Prediction of ovarian reserve based on day-3 serum follicle stimulating hormone concentrations during the pituitary suppression cycle using a gonadotropin releasing hormone agonist in patients undergoingin vitrofertilization–embryo transfer

2004 ◽  
Vol 18 (6) ◽  
pp. 335-340 ◽  
Author(s):  
T Onagawa ◽  
H Shibahara ◽  
Ayustawati ◽  
S Machida ◽  
Y Hirano ◽  
...  
Keyword(s):  
Embryo Transfer ◽  
Ovarian Reserve ◽  
Follicle Stimulating Hormone ◽  
Gonadotropin Releasing Hormone ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Pituitary Suppression ◽  
Stimulating Hormone

No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial

2016 ◽  
Vol 34 (22) ◽  
pp. 2568-2574 ◽  
Author(s):  
Isabelle Demeestere ◽  
Pauline Brice ◽  
Fedro A. Peccatori ◽  
Alain Kentos ◽  
Jehan Dupuis ◽  
...  
Keyword(s):  
Ovarian Reserve ◽  
Ovarian Function ◽  
Follicle Stimulating Hormone ◽  
Gonadotropin Releasing Hormone ◽  
Control Group ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Stimulating Hormone

Purpose We have reported previously that after 1-year follow up, gonadotropin-releasing hormone agonist (GnRHa) did not prevent chemotherapy-induced premature ovarian failure (POF) in patients with lymphoma, but may provide protection of the ovarian reserve. Here, we report the final analysis of the cohort after 5 years of follow up. Patients and Methods A total of 129 patients with lymphoma were randomly assigned to receive either triptorelin plus norethisterone (GnRHa group) or norethisterone alone (control group) during chemotherapy. Ovarian function and fertility were reported after 2, 3, 4, and 5 to 7 years of follow up. The primary end point was POF, defined as at least one follicle-stimulating hormone value of > 40 IU/L after 2 years of follow up. Results Sixty-seven patients 26.21 ± 0.64 years of age had available data after a median follow-up time of 5.33 years in the GnRHa group and 5.58 years in the control group (P = .452). Multivariate logistic regression analysis showed a significantly increased risk of POF in patients according to age (P = .047), the conditioning regimen for hematopoietic stem cell transplant (P = .002), and the cumulative dose of cyclophosphamide > 5 g/m2 (P = .019), but not to the coadministration of GnRHa during chemotherapy (odds ratio, 0.702; P = .651). The ovarian reserve, evaluated using anti-Müllerian hormone and follicle-stimulating hormone levels, was similar in both groups. Fifty-three percent and 43% achieved pregnancy in the GnRHa and control groups, respectively (P = .467). Conclusion To the best of our knowledge, this is the first long-term analysis confirming that GnRHa is not efficient in preventing chemotherapy-induced POF in young patients with lymphoma and did not influence future pregnancy rate. These results reopen the debate about the drug’s benefit in that it should not be recommended as standard for fertility preservation in patients with lymphoma.

Sign in / Sign up

Export Citation Format

Share Document